ARTICLE | Financial News

3-V Biosciences raises $28.5M series D

January 1, 2015 12:24 AM UTC

3-V Biosciences Inc. (Menlo Park, Calif.) raised $28.5 million in a series D round co-led by New Enterprise Associates; Kleiner Perkins Caufield & Byers; and Rock Springs Capital Management. Ally Bridge Group and other new investors also participated.

3-V expects early efficacy data in 2015 from a Phase I trial of TVB-2640, an oral fatty acid synthase ( FASN; FAS) inhibitor to treat advanced solid tumors. The company said TVB-2640 is the first FASN inhibitor to enter human trials. ...